Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.

导出 OA

翻译打印收藏纠错

第一作者： David B,Price

第一单位： Observational and Pragmatic Research Institute, Singapore.

作者： David B,Price ^[1] ; William,Henley ^[2] ; José Eduardo Delfini,Cançado ^[1] ; Leonardo M,Fabbri ^[3] ; Huib A M,Kerstjens ^[4] ; Alberto,Papi ^[5] ; Nicolas,Roche ^[6] ; Elif,Şen ^[7] ; Dave,Singh ^[8] ; Claus F,Vogelmeier ^[9] ; Sara,Barille ^[10] ; Elena,Nudo ^[11] ; Victoria,Carter ^[12] ; Derek,Skinner ^[12] ; Rebecca,Vella ^[1] ; George,Georges ^[1]

作者单位： Observational and Pragmatic Research Institute, Singapore. ^[1] Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. ^[2] Health Statistics Group, Institute of Health Research, University of Exeter Medical School, Exeter, UK. ^[3] Santa Casa de São Paulo Medical School, São Paulo, Brazil. ^[4] Respiratory Medicine, Department of Translational Medicine, University of Ferrara, Ferrara, Italy. ^[5] Department of Pulmonary Diseases, University of Groningen and University Medical Centre Groningen, and Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, Netherlands. ^[6] Respiratory Medicine, University of Ferrara, Ferrara, Italy. ^[7] Department of Respiratory Medicine, APHP-Centre University of Paris, Cochin Institute, Paris, France. ^[8] Department of Pulmonary Medicine, Ankara University School of Medicine, Ankara, Turkey. ^[9] Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. ^[10] Department of Internal Medicine, Pulmonary and Critical Care Medicine, University of Marburg, Member of the German Centre for Lung Research (DZL), Marburg, Germany. ^[11] Global Medical Affairs, Chiesi Farmaceutici, S.p.A., Parma, Italy. ^[12] Global Clinical Development, Chiesi Farmaceutici, S.p.A., Parma, Italy. ^[13]

关键词 COPD extrafine beclomethasone fluticasone inhaled corticosteroids pneumonia

主题词投药, 吸入(Administration, Inhalation);成年人(Adult);倍氯米松(Beclomethasone);队列研究(Cohort Studies);人类(Humans);肺炎(Pneumonia);肺疾病, 慢性阻塞性(Pulmonary Disease, Chronic Obstructive);治疗结果(Treatment Outcome)

DOI 10.2147/COPD.S342357

PMID 35210765

发布时间 2022-05-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

International journal of chronic obstructive pulmonary disease

355-370页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.

International journal of chronic obstructive pulmonary disease

相似文献

International journal of chronic obstructive pulmonary disease

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.

International journal of chronic obstructive pulmonary disease

相似文献

International journal of chronic obstructive pulmonary disease

相关期刊

检索历史清除